Objectives: To study innate immune pathways in patients undergoing hepatopancreaticobiliary surgery to understand mechanisms leading to enhanced inflammatory responses and identifying biomarkers of adverse clinical consequences. Background: Patients undergoing major abdominal surgery are at risk of lifethreatening systemic inflammatory response syndrome (SIRS) and sepsis. Early identification of at-risk patients would allow tailored postoperative care and improve survival. Methods: Two separate cohorts of patients undergoing major hepatopancreaticobiliary surgery were studied (combined n ¼ 69). Bloods were taken preoperatively, on day 1 and day 2 postoperatively. Peripheral blood mononuclear cells and serum were separated and immune phenotype and function assessed ex vivo. Results: Early innate immune dysfunction was evident in 12 patients who subsequently developed SIRS (postoperative day 6) compared with 27 who did not, when no clinical evidence of SIRS was apparent (preoperatively or days 1 and 2). Serum interleukin (IL)-6 concentration and monocyte Toll-like receptor (TLR)/NF-kB/IL-6 functional pathways were significantly upregulated and overactive in patients who developed SIRS (P < 0.0001). Interferon a-mediated STAT1 phosphorylation was higher preoperatively in patients who developed SIRS. Increased TLR4 and TLR5 gene expression in whole blood was demonstrated in a separate validation cohort of 30 patients undergoing similar surgery. Expression of TLR4/5 on monocytes, particularly intermediate CD14 þþ
T he systemic inflammatory response syndrome (SIRS) is associated with significant patient morbidity and mortality. 1 Systemic inflammatory response syndrome is a clinically defined state that represents activation of inflammatory, innate immune, coagulation, and repair pathways and is frequently observed in hospitalized patients. Overall, there is a 7-fold increase in 28-day mortality in hospitalized patients with SIRS compared with those without. 2 The incidence of postoperative sepsis (SIRS plus presumed or confirmed infection) is high in major operations; 16.7% after distal pancreatic resections, 3 or 32% to 46% in digestive and gynecological tumor resections. 4 Identification of patients at risk of SIRS would allow preemptive therapy that may improve outcomes.
A key step in the initiation of SIRS is activation of pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). 5 A wide range of PRRs have been described including membrane-bound Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), or cytoplasmic receptors such as NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs). The paradigm for PRR activation is TLR4 interacting with lipopolysaccharide (LPS), a component of Gram-negative bacteria. There are at least 11 other members of the TLR family in humans and each is associated with activation by particular PAMPs. 6 TLR5 is activated by flagellin, which is a component of motile bacteria. 7 After receptor ligation, adapter proteins are recruited and intracellular signaling pathways eventually lead to the activation (phosphorylation) of key transcription factors such as NF-kB and ERK1/2 among others. 8, 9 These in turn drive the production of important pro-and anti-inflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor (TNF)-a, and IL-10. 10 After surgery, dysregulated release of pro-inflammatory cytokines has been associated with postoperative complications. Many groups have attempted to identify biomarkers that predict poor outcomes after surgery, but the majority of these tests are inconvenient to run in a clinical setting or involve unwieldy or expensive techniques. 11, 12 Despite this complexity, several reports have suggested that an elevated IL-6 concentration in the early postoperative period is a good predictor of postoperative SIRS. 4, 13 Complex abdominal surgery can lead to the release of a broad array of PRR agonists including DAMPs released from the trauma itself, PAMPs released from commensal (eg, because of gut translocation), or environmental contamination. In specialist surgical centers with technical expertise and dedicated perioperative care, it is likely that the release of DAMPs and PAMPs related to the surgical procedure is relatively constant across patients, suggesting that this is not the only determinant that distinguishes patients who develop SIRS from those who do not. We hypothesize that the development of SIRS is a function of the responsiveness of host innate immune systems-principally circulating monocytes-to a given DAMP or PAMP load. In this study, we have focused on TLR4 and TLR5 and their bacterial ligands as examples of PRR sensing systems and also because Gram-negative (LPS) and motile (flagellin) From the
MATERIALS AND METHODS

Patient Selection
We included adult patients who were undergoing major liver or pancreatic (nonemergency) resection at Barts Health HPB Centre between August 2011 and November 2013 and who gave written informed consent. Exclusion criteria were active concurrent inflammatory disease (eg, inflammatory bowel disease and rheumatoid arthritis), preoperative sepsis, and treatment with chemotherapeutic or regular anti-inflammatory medications.
Data Collection
Demographic, clinical, hematological and histological data were collected prospectively from patient notes and the Electronic Patient Record system and included information on comorbidities, indication for surgery, cancer diagnosis, duration of the procedure, length of hospital stay, and in-hospital mortality. Patients were examined and observations charts reviewed daily by the clinical team for the presence of SIRS or infection, starting on the morning after surgery (day 1). Systemic inflammatory response syndrome was defined according to international convention when 2 or more of the following criteria were present: (1) body temperature less than 368C or more than 388C; (2) heart rate more than 90 beats per minute; (3) tachypnea with breathing rate more than 20 breaths per minute; and (4) peripheral white cell count (WCC) less than 4000 cells/mm 3 or more than 12,000 cells/mm 3 .
14 Definitions of infection were agreed a priori by the investigators and were based on the Center for Disease Control and Prevention definitions. 15 
Venous Blood Sampling and Separation
Bloods were taken at clinically indicated times preoperatively, and on day 1 and day 2 postoperatively. Serum was collected and stored at À808C. Peripheral blood mononuclear cells (PBMCs) were separated by centrifugation over Ficoll Paque (GE Healthcare, Little Chalfont, UK) to provide a source of monocytes. The resulting interface was aspirated, washed in phosphate buffered saline (PBS), and stored in 10% dimethyl sulfoxide freezing solution at À808C.
TLR Stimulation and Cytokine Production
A total of 2 Â 10 6 PBMCs were resuspended in 1 mL of complete medium (RPMI 1640 containing 10% fetal calf serum 10 U/mL of penicillin G sodium, 10 mg/mL of streptomycin sulfate), then rested for 2 hours and equally divided into a 12-well plate. Each well contained 1 mL of complete medium per well. The cells were stimulated with 2 ng/mL of Salmonella typhi lipopolysaccharide (LPS, Sigma, Gillingham, UK) and 10 mg/mL of S. typhi flagellin (Invivogen, Toulouse, France) for 24 hours. Supernatants were stored at À808C. IL-6, TNF-a, and IL-10 concentrations were measured in thawed supernatants and patient serum samples using commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN). Quantification of NF-kB, ERK1/2, and STAT1 Phosphorylation in CD14 R Cells (Multiplex PhosFlow)
Measurement of TLR4 and TLR5 Cell Surface Expression on Monocytes
Peripheral blood mononuclear cells were prepared as for TLR stimulation above, and the contents of each well of a 6-well plate were resuspended in 200 mL of complete medium. After incubation, the cells were aspirated from each well and transferred into FACS tubes. Each well was washed with 1 mL of complete medium to ensure complete removal of any cells that had adhered to the base of the well. The samples were then centrifuged at 300 g for 5 minutes and the cells resuspended in complete medium.
The following were added to the PBMCs in FACS tubes and incubated for 15 minutes in a water bath at 378C: 10 mg/mL of flagellin, 2 ng/mL of LPS, 10,000 u/mL of IFN2a, or no agonist. Cells were fixed in 1% paraformaldehyde, permeabilized with Perm buffer III (BD Biosciences, San Jose, CA) on ice in the dark for 30 minutes. Peripheral blood mononuclear cells were then washed in FACS buffer (500 mL of PBS, 10 mL of fetal calf serum, 0.1 g of sodium azide, and 0.18 g of ethylenediaminetetraacetic acid) and the antibody cocktail added: antiphosphorylated STAT1 (fluorescein isothiocyanate), antiphosphorylated NF-kB (phycoerythrin), antiphosphorylated ERK1/2 (Alexa Fluor 647) (BD Biosciences, Oxford, UK), and antiCD14 (Pacific Blue) (Biolegend, Cambridge, UK). The PBMCs were incubated at room temperature for 45 minutes in the dark, washed with FACS buffer, and resuspended in 300 mL of FACS buffer and immediately analyzed on a Canto II flow cytometer. Color compensation and gating were performed to select CD14 þ cells for analysis of NF-kB, STAT1, and ERK1/2 phosphorylation. In each experiment, specific antibody staining was determined with reference to an isotype-matched control. The data were analyzed using WinList 3D version 3.1. (Verity Software House, Topsham, ME) and expressed as the percentage of CD14 þ cells that were positive for each phosphoantigen above isotype control.
Serum Conditioning of Healthy Control PBMCs
Peripheral blood mononuclear cells from healthy controls were prepared in the same way as patient samples. In serum conditioning experiments, 500 mL of patient serum was added to each well of a 12-well plate before stimulation with the same agonists as above. Supernatants were stored at À208C until analysis by enzyme-linked immunosorbent assay. Peripheral blood mononuclear cells were then used for flow cytometry as described above.
Gene Expression
Blood was collected at each time point in a PAXGene blood RNA tube (PreAnalytix, Hilden, Germany). Total RNA was extracted using PAXGene blood RNA kits (PreAnalytix). Samples were analyzed for RNA integrity and reverse transcribed to complementary DNA (cDNA). Gene expression was quantified by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) using TLR4 and TLR5 Taqman assays (Applied Biosystems, Foster City, CA), which spanned the final 2 exons of the most common isoform of each gene, and were carried out on a 7900HT apparatus, Life Tech Each sample was assayed in triplicate. Reference genes [b2 microglobulin (B2 M) and Ubiquitin C (UBC)] were selected empirically from a panel of 6. 17 Relative quantification was calculated using the standard delta-delta methodology. Results were expressed as a normalized ratio of candidate gene/reference gene.
Statistical Analysis
All data presented in the Results section were tested for normality using the D'Agostino Pearson test. Continuous data were analyzed using appropriate statistical tests (unpaired t test, MannWhitney test) on the basis of normality of distribution. Differences in categorical variables were calculated using a x 2 or Fisher exact test as appropriate. All statistical analysis was performed using GraphPad Prism and P < 0.05 was considered significant.
RESULTS
Serum IL-6 Concentrations Predict Postsurgical SIRS
We examined immune parameters associated with the development of SIRS in a cohort of 39 patients undergoing ''high-risk'' surgical procedures (Table 1) . Mean patient age was 63.2 years (range, 22-85), 52% (n ¼ 20) were male, and 95% (n ¼ 37) were white ( Table 1 ). A total of 24 patients underwent pancreaticoduodenectomy, 9 major liver resection, 4 distal pancreatectomy, 1 palliative bypass procedure, and 1 excision of the choledochal cyst. Of these 39 patients, 12 (30.7%) subsequently developed SIRS between postoperative days 2 and 12 (median day 6). The cause of each complication and the outcome are shown in Table 2 . There were no differences in preoperative hematology (hemoglobin/hematocrit, WCC, platelets) or biochemistry (urea, creatinine, bilirubin) between patients who developed SIRS and those who had an uneventful recovery. The median length of hospital stay for patients who developed postoperative SIRS was significantly longer than for those who had an uneventful recovery [22 (range, 12-52) vs 12 (range, 6-24) days; P < 0.001]. All patients were managed with the same anaesthetic regimen, and there were no differences in SIRS rates among the 3 surgeons who performed the procedures. There were no significant differences in intraoperative transfusion of blood products or key clinical parameters [hemoglobin, WCC, creatinine, bilirubin, or C-reactive protein (CRP)] between patients who developed SIRS and those who did not (Table 1 ). There were also no significant differences in operative time and blood loss volume, except in 6 patients who underwent right hemihepatectomy, which is a complex procedure with longer duration (295 minutes vs 198 minutes; P < 0.05) and greater blood loss (2695 mL vs 1344 mL; P < 0.01).
We examined postoperative serum concentrations of selected inflammatory cytokines (Fig. 1) . Before the overt development of SIRS, we found that serum concentrations of IL-6 were higher in patients who developed SIRS after surgery compared with those who did not ( Fig. 1A; 122.4 pg/mL vs 92.1 pg/mL on day 2; P < 0.05). Of note, these changes in IL-6 cytokine levels predated changes in any of the clinical parameters assessed. Postoperative serum concentrations of the anti-inflammatory cytokine IL-10 were reduced in both groups of patients compared with preoperative levels ( Fig. 1B ; 211.5 pg/mL preoperatively vs 151.1 pg/mL on day 2; P < 0.02), but there were no significant differences between groups. There were no changes in serum TNF-a concentration in this early postoperative period (Fig. 1C) .
Monocyte TLR Expression Is Associated With Postoperative SIRS
Ligation of microbial products by TLRs, including TLR4 and TLR5, leads to rapid production of pro-inflammatory cytokines such as IL-6. We tested the hypothesis that monocytes (a major producer of pro-inflammatory cytokines) expressed different levels of TLRs in patients who went on to develop SIRS. Expression levels (MFI) of TLR4 and TLR5 on CD14 þ monocytes sampled on postoperative day 1 were 2.1-fold and 2.4-fold greater, respectively, in patients who developed postoperative SIRS than in those with an uneventful recovery ( Fig. 2 , P < 0.0001). Similar results were seen on postoperative day 2, with 2.1-fold and 2.7-fold higher TLR4 and TLR5 expression (MFI) in patients who developed SIRS. There were no significant preoperative differences in TLR4 or TLR5 expression between the 2 groups of patients. This level of TLR expression in patients did not differ significantly from that seen in monocytes from 14 healthy control volunteers [7 males and 7 females; mean age, 37.4 years (range, 21-62 years)]. In patients who did not develop postoperative SIRS, there was no significant change in monocyte TLR4 and TLR5 expression in the perioperative period. However, in the SIRS group, there was a significant increase in expression of TLR4 (P < 0.0002) and TLR5 (P < 0.0001) early after surgery (individual patient data from postoperative days 1 and 2 are shown in Supplemental Digital Content 1, available at http://links.lww.com/ SLA/A784).
Consistent with these data, on postoperative day 2 (but not preoperatively; Fig. 3A) , monocytes in patients who developed SIRS produced significantly more IL-6 after ex vivo stimulation with the TLR4 agonist LPS (1.11 ng/mL vs 300 pg/mL; P < 0.0001) or TLR5 agonist flagellin (892 pg/mL vs 148 pg/mL; P < 0.0001) when compared with monocytes in patients who did not develop SIRS (Fig. 3C) . Stimulation with flagellin on postoperative day 1 also induced more IL-6 in patients who went on to develop SIRS compared with those who did not ( Fig. 3B ; 252 pg/mL vs 132 pg/ mL; P ¼ 0.02), as was the case with LPS-induced IL-10 production Fig. 3E ; 275 pg/mL vs 182 pg/mL; P ¼ 0.03). No differences were seen in TLR-mediated TNF-a (Figs. 3G, H) although the tonic production of TNF-a by unstimulated monocytes was significantly reduced in the immediate postoperative period compared with preoperatively (preoperative mean, 200 pg/mL, 109 pg/mL on day 1, 91 pg/mL on day 2; P < 0.0001 analysis of variance). This change was noted in both patient groups. In contrast, IL-6 or IL-10 production by unstimulated monocytes did not differ between preoperative and early postoperative samples. These findings were unlikely to be due to the effects of stable circulating soluble mediators (including IL-6 itself), because changes in TLR4 or TLR5 expression and ligand-stimulated cytokine production could not be replicated by culturing blood monocytes from healthy controls in patient serum, regardless of whether or not the serum was derived from a patient who subsequently developed SIRS (Supplemental Digital Content 2, available at http://links.lww.com/ SLA/A785). After LPS and flagellin stimulation, there was no significant difference in IL-6, TNF-a, or IL-10 production between PBMCs treated with sera among patients who developed SIRS or patients who did not (Supplemental Digital Content 3, available at http://links.lww.com/SLA/A786).
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We next sought to determine whether the observed intrinsic enhancement of monocyte TLR activation and cytokine production was associated with activation of canonical signaling pathways. We developed a multiplex assay on the basis of the BD Bioscience PhosFlow system to study the phosphorylation of the key intracellular signaling molecules NF-kB, ERK1/2, and STAT1 (Supplemental Digital Content 4, available at http://links.lww.com/SLA/A787, and Fig. 4 ). In line with our ex vivo cytokine production data, monocyte stimulation with LPS or flagellin resulted in greater NF-kB phosphorylation in patients who developed SIRS compared with patients who did not on postoperative day 1 and day 2 (Figs. 4B, C) . LPS stimulation resulted in a 3.7-fold increase in the percentage of phosphorylated NF-kB-positive CD14 þ cells on day 1 compared with non-SIRS patients (P < 0.01) and 11.2-fold increase on day 2 (P < 0.005). Flagellin stimulation resulted in a 3.8-fold increase in NF-kB phosphorylation on day 1 compared with non-SIRS patients (P < 0.05) and an 8.9-fold increase on day 2 (P < 0.005).
ERK1/2 phosphorylation in blood monocytes was consistently lower in patients who developed SIRS than in patients who did not when assessed in unstimulated (P < 0.04), LPS-stimulated (P < 0.03), or flagellin-stimulated cells (P < 0.03) as assessed on postoperative day 2 (Fig. 4I) . A similar trend was observed in monocytes from day 1, but these comparisons did not reach statistical significance. There were no preoperative differences in unstimulated, LPS-or flagellin-induced NF-kB, or ERK 1/2 phosphorylation. However, preoperative induction of STAT1 phosphorylation by IFNa cytokine (but not LPS or flagellin) was 1.9-fold greater in monocytes among patients who developed SIRS compared with those who did not ( Fig. 4D ; P < 0.05 by univariate analysis).
Taken together, these data suggest that patients who proceed to develop SIRS have increased TLR4 and TLR5 expression on blood monocytes in the immediate postoperative period. The functional consequence of this enhanced postsurgical response is increased activation of the NF-kB-IL-6 signaling pathway. The strong positive correlations between TLR expression and agonist-induced IL-6 production suggest that these phenomena are linked in vivo (Supplemental Digital Content 5, available at http://links.lww.com/SLA/ A788).
Elevated TLR Expression on Intermediate Monocytes Among Patients Who Develop SIRS
To determine which monocyte subset was involved in the altered expression of TLR4 or TLR5, we studied CD16 expression to distinguish classical (CD14 þþ , CD16
þþ ) monocytes (Supplemental Digital Content 6, available at http://links.lww.com/SLA/ A789). Preoperatively, the proportions of intermediate monocytes were higher (P < 0.01; Fig. 5 ) and those of classical monocytes were lower (P < 0.05) in patients who developed SIRS compared with those who did not, but there were no significant postoperative differences in these proportions. In all patients analyzed here, monocyte expression of TLR4 (P < 0.0001) and TLR5 (P < 0.0001) was highest in the intermediate subset, and the increases in TLR4 and TLR5 levels seen in patients who proceeded to develop SIRS were restricted to this subset (Supplemental Digital Content 7, available at http://links.lww.com/SLA/A790). In keeping with the data from total monocytes, there were no preoperative differences in TLR4 or TLR5 expression in any subset. However, on both postoperative days 1 and 2, TLR4 (P < 0.0004) and TLR5 (P < 0.0001) expression on intermediate monocytes was significantly higher in patients who developed SIRS than in those who had an uneventful recovery (Fig. 5) . On day 2, TLR4 and TLR5 expression levels were 1.5-fold higher in patients who developed SIRS compared with those who did not. Thus, TLR4 and TLR5 expression on intermediate monocytes progressively increased over time in patients who subsequently developed SIRS, whereas they remained constant in patients who had a noneventful recovery.
TLR5 Expression Predicts SIRS
The markers of immune dysfunction identified in this cohort of patients correctly identified all patients who subsequently developed clinical SIRS. We calculated the area under the receiveroperator curve (AUROC, Fig. 6 ) to estimate the accuracy of those tests that could be performed conveniently in a clinical pathology setting as predictors of SIRS. The AUROC, sensitivity, and specificity for IL-6, TLR4, and TLR5 expression on day 1 and day 2 were substantially greater than that for WCC on day 1, indicating greater accuracy for these tests compared with routine clinical parameters (Table 3) . To confirm that increased monocyte expression in the postoperative period was associated with SIRS, we took advantage of the availability of a second, independently collected cohort of 30 different patients from the same hospital undergoing similar surgery in whom whole blood gene expression profiling by Taqman PCR had been performed along with stored serum to assess IL-6 levels. The baseline demographic and clinical characteristics of patients in the confirmatory cohort were similar to those of the index group, with no significant differences in sex, age, ethnicity, intraoperative time, receipt of intraoperative blood products, preoperative biochemistry, and hematology (Tables 1 and 4 ). In the confirmatory cohort, 8 patients (26.7%) developed SIRS in the postoperative period, all associated with subsequent development of infection. As in the original cohort, patients who developed SIRS had a significantly longer in-patient stay (median, 22 days vs 9 days; P < 0.001). Patients in the confirmatory cohort who developed SIRS had significantly greater IL-6 concentration in the serum (233.9 pg/mL vs 71 pg/mL; P ¼ 0.002) on day 2, but this did not reach statistical significance on day 1 (Supplemental Digital Content 8, available at http://links.lww.com/SLA/A791). TLR5 gene expression increased significantly postoperatively compared with preoperative samples in this cohort. In keeping with the findings from our earlier proteinbased studies in selected monocytes, the expression of TLR5 mRNA in whole blood was 35% greater in patients who went on to develop SIRS compared with those who did not ( Fig. 7 ; P < 0.01).
DISCUSSION
Systemic inflammatory response syndrome is a common complication of major surgery, and identifying patients who will develop SIRS early in the postoperative period may allow changes in management that may lead to improved outcomes. Here, we report that serum concentration of IL-6 cytokine on postoperative days 1 and 2 can be used to distinguish patients who will develop SIRS from those who will not-a median of 5 days before the onset of clinical signs in our series. We have studied the mechanisms that drive IL-6 production and show that in patients who develop postoperative
FIGURE 3. Effects of TLR stimulation on PBMC cytokine production after major hepatopancreaticobiliary surgery.
Annals of Surgery Volume 263, Number 5, May 2016
Monocyte Dysfunction in Postoperative SIRS SIRS, both LPS and flagellin can drive monocyte IL-6 production to a greater extent than in patients who do not, and this is likely to be mediated by upregulated TLR gene expression, as indicated both by studies of protein expression in an experimental cohort and confirmed by mRNA Taqman PCR in whole blood among patients in a confirmatory cohort. As such, we have identified TLR expression on monocytes, especially TLR5 on intermediate monocytes, as early and accurate biomarkers for postoperative SIRS. IL-6 is a pleotropic inflammatory cytokine that forms an important part of the early response to injury or infection. It activates vascular endothelial cells increasing permeability and vascular leakage, stimulates the hepatic production of acute-phase proteins (including CRP), promotes bone marrow production of inflammatory and immune cells, and can activate B and T lymphocytes. 18 We and others have observed that IL-6 is elevated in patients who develop SIRS, and although IL-6 concentrations were lower in our series than those reported by studies of similar patient groups, 4 it is a consistent finding that IL-6 levels on day 1 can distinguish patients who will develop SIRS from those who will not. 13 We further investigated the mechanisms underlying these data, and detected that the TLR/NFkB/IL-6 axis is overactive in patients who develop SIRS. Although responses to both TLR4 and TLR5 agonists were increased, the abnormality is specific to the NF-kB but not ERK1/2 signaling, and only IL-6 production was elevated (not TNF-a or IL-10), suggesting that additional intracellular factors determine selectivity of response. Activation of NF-kB in CD14 þ monocytes has recently been shown to be associated with poor recovery after orthopedic surgery (recovery from fatigue, functional impairment of the hip, and pain after surgery), although this study did not explore the mechanisms or pathways that result in transcription factor activation. 19 We have focused on 2 key TLRs that mediate host responses to bacterial products, LPS, and flagellin that together represent a large proportion of bacteria found in the gut and elsewhere, although the exact source of these products is as yet unclear. The role of additional DAMPs or PAMPs and any of the more than 40 PRRs (eg, lipoteichoic acid ligation of TLR2 or uric acid and NALP3) is currently unknown. We postulate that pro-inflammatory signals (PAMPs or DAMPs), perhaps from dead cells or from host commensal bacteria, are liberated during surgery and may act as potential triggers of inflammation.
TLR-mediated production of type-1 IFN (IFNa/b) is a very early step in the initiation of inflammation. Autocrine and paracrine type-1 IFN binds to the cognate receptor and activates signaling mediators including STAT1 and STAT2, which in turn drive IRFmediated gene expression and amplify the response. 20 It is therefore of particular interest to note preoperative differences in IFNainduced STAT1 phosphorylation between patients who develop SIRS and those who do not. One attractive hypothesis is that individuals who develop SIRS are predisposed to excessive inflammation with a ''primed'' STAT1 response. For a given degree of tissue damage, endogenous bacterial translocation (or an alternative stimulus), this ''preprimed'' state facilitates a more robust inflammatory response, which may include expression of TLRs (known IFN-stimulated genes). 21 In keeping with this, we have shown an increased abundance of TLR5 mRNA in patients who develop SIRS. However, our data do not allow us to identify the mediator of the change, although inhibitors of TLR and IFN signaling-such as suppressor of cytokine signaling and protein inhibitor of activate STATs proteins-are potential candidates.
Patients who develop SIRS have a greater proportion of CD14 þþ /CD16 þ (intermediate) monocytes preoperatively. Intermediate monocytes are considered pro-inflammatory with greater production of TNF-a and IL-1b after stimulation with LPS, increased interaction with endothelial cells, and greater chemokine production compared with other subsets. 22 We show that intermediate monocytes express higher levels of TLR4 23 and TLR5 (previously not known) than CD14
þþ nonclassical monocytes at all time points. The increased expression of TLR4 and TLR5 detected on monocytes among patients who develop SIRS was restricted to the intermediate subset, and accordingly, the accuracy of predicting SIRS is increased by measuring TLR4 and TLR5 on intermediate monocytes only (compared with total monocytes).
The incidence of postoperative SIRS in our main cohort was 31.7%, and SIRS was associated with a significantly increased length of hospital stay (22 days vs 13 days) and a higher mortality rate (15.3%). Despite the heterogeneity of the operations included in this study, these outcomes are in keeping with published data, 24, 25 suggesting that our conclusions are applicable more widely. The diagnostic accuracy of the tests proposed in this study will now require validation in a larger, independent cohort that includes patients undergoing a broader range of surgery, and it may be possible to refine our protocols yet further to enable these tests to be conducted in a routine clinical setting.
The patients who developed SIRS in this study had worse outcomes than those who did not develop SIRS, in terms of length of hospital stay, use of intravenous antibiotics, return to highdependency unit, or further radiological or surgical procedures. Organ dysfunction was not a common feature and only seen in the patients who died. This highlights the potential clinical utility of 
Monocyte Dysfunction in Postoperative SIRS the markers we identify as sensitive indicators of events that can be avoided or whose impact can be reduced (eg, by the early introduction of antibiotics), rather than indicators of extreme complications that are likely to be irredeemable. Currently used ''early warning'' scoring systems are based on routinely collected clinical data, but these can be difficult to interpret in postoperative patients in whom clinical observations may already be deranged. These scores are therefore unable to identify patients at risk until SIRS is established, or nearly established. Our current experience suggests that this is too late to implement preventative measures such as low-dose glucocorticoids, antibiotics, and/or prolonged stay on the high-dependency unit. In contrast, the novel approach that we propose may permit the use of interventions that are targeted against key inflammatory mediators of SIRS pathogenesis early after surgery, particularly given that none of the patients in the current study had met SIRS criteria at the time of blood sampling. This suggests that at this time, general or specific interventions can be implemented to avert SIRS. Although targeted therapies such as specific TLR4 inhibitors did not alter outcomes in patients with severe sepsis, 26, 27 this may be because patients were already critically unwell and at advanced stages of SIRS when given a TLR4 antagonist. We hypothesize that treating patients with TLR4 inhibitors or agents that impair signaling through TLR5 or NF-kB may provide therapeutic benefit before the clinical manifestations of SIRS or sepsis become apparent.
CONCLUSIONS
We have identified a novel mechanism by which innate immune dysfunction occurs early in the postoperative period in patients who develop SIRS-long in advance of clinical signs.
Abnormally elevated IL-6 levels in patients who will develop SIRS are related to upregulated TLR4 and TLR5 expression and preferential activation of NF-kB. We hypothesize that before surgery, patients who develop SIRS exhibit an increased proportion of intermediate monocytes that are primed to react in this way. Clearly, more work is needed to develop the clinical application of the markers we have identified here. However, we believe that the strategy we have employed here to study the mechanisms of disease have identified novel biomarkers and potential targets for therapeutic intervention.
